Company / Operating Income
Anika Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$11.1M
FY2025
5-year range
-$28.3M / $34.2M
FY2021-FY2025
Trend
-116.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$28M in FY2022 to $61M in FY2016.
Based on SEC 10-K filings.
-$11M in FY2025.
Declined from $844,000 to -$11M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 116.6% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$11.1M | -116.6% |
| FY2024 | -$5.1M | -704.4% |
| FY2023 | $844.0K | +103.0% |
| FY2022 | -$28.3M | -182.7% |
| FY2021 | $34.2M | +57.5% |
| FY2020 | $21.7M | -52.4% |
| FY2019 | $45.7M | -9.6% |
| FY2018 | $50.6M | +5.1% |
| FY2017 | $48.1M | -21.7% |
| FY2016 | $61.4M | +88.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026